WGS is a comprehensive genetic test that analyses an individual’s entire genome to identify genetic variations linked to diseases. It can quickly detect most genetic issues, including rare conditions that might otherwise go undiagnosed. The availability of the test in Qatar, significantly eliminates the need to send samples abroad, reducing turnaround times from months to weeks.
This is particularly crucial for critically ill patients where timely diagnosis can be lifesaving. , CEO of Sidra Medicine, highlighted that the implementation of clinical-grade whole genome sequencing marks a significant advancement for healthcare in Qatar and globally. , Chief Research Officer at Sidra Medicine, on the other hand, noted that this milestone establishes Sidra Medicine as the first facility in Qatar to provide clinical-grade whole genome testing.
As the cost of WGS continues to decrease, Sidra Medicine will consider making it a routine part of its paediatric care services especially for young patients with unexplained health conditions. The programme will also enable proactive and preventive measures for the hospital’s patients including fetuses and young babies, by identifying genetic risks in advance and developing personalised treatment plans. , Chair of the Department of Pathology at Sidra Medicine, said that this methodology leads to more targeted treatments and improved patient outcomes.
.
